Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics


Mirum Pharmaceuticals, Inc. - common stock (MIRM): $18.00

-0.04 (-0.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $18.00 52-week high $27.43
Prev. close $18.04 52-week low $15.22
Day low $17.88 Volume 90,500
Day high $18.28 Avg. volume 117,887
50-day MA $17.77 Dividend yield N/A
200-day MA $19.07 Market Cap 548.15M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021

FOSTER CITY, Calif., Jun 16, 2021--Mirum Pharmaceuticals to Showcase Analyses from its Rare Liver Disease Programs at The International Liver Congress 2021

Yahoo | June 16, 2021

Mirum adds veteran biotechnology executive Carol Brosgart to board of directors

Mirum Pharmaceuticals ([[MIRM]] -0.5%) announces the appointment of veteran biotechnology executive Carol Brosgart as an independent director to its board of directors.Brosgart currently serves as an industry consultant and scientific advisor, and as an independent director for several public and privately held biotechnology companies.She brings extensive clinical, public policy, advocacy and corporate experience to...

Seeking Alpha | June 7, 2021

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

Yahoo | June 7, 2021

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021

Mirum to Present Maralixibat Data and Host Symposium at the 6th WCPGHAN Annual Meeting 2021

Yahoo | May 26, 2021

We're Not Very Worried About Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | May 12, 2021

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo 2.62%
3-mo -8.35%
6-mo -2.54%
1-year -8.40%
3-year N/A
5-year N/A
YTD 3.09%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8353 seconds.